REVELATION BIOSCIENCES Business Summary

Revelation Biosciences, Inc. (REVB) is a clinical-stage biopharmaceutical company that operates as a pre-revenue entity, generating capital primarily through equity financing, warrant exercises, and strategic partnerships. The company’s business model centers on the development of its proprietary Gemini formulation, a systemic Toll-like receptor 4 (TLR4) agonist designed to harness "trained immunity" to prevent or treat systemic inflammation and infection. Its primary business segments are organized around clinical programs: GEM-AKI for the prevention of acute kidney injury, GEM-CKD for chronic kidney disease, and GEM-PSI for post-surgical infection prevention. As of early 2026, the company has reached a pivotal agreement with the FDA on a Phase 2/3 approval pathway for Gemini in AKI. Revelation competes in the high-risk biotechnology sector against peers such as Sensei Biotherapeutics (SNSE), Longeveron (LGVN), and BioAtla (BCAB), positioning itself as a niche leader in innate immune system preconditioning for critical care nephrology. The leadership team is led by Co-founder James Rolke, who serves as Chairman and CEO; Rolke brings over 30 years of biotech experience, including his previous tenure as Chief Scientific Officer at La Jolla Pharmaceutical Company, where he oversaw multiple FDA approvals. Co-founder and CFO Chester Zygmont, III, manages the company’s financial strategy and has over 20 years of experience in corporate finance and social enterprise. The scientific direction is further supported by Robin Marsden, Senior Vice President of Biology. Revelation’s board includes notable industry figures such as Dr. Lakhmir Chawla, CEO of Exthera Medical and a renowned expert in nephrology. The company’s institutional backing includes significant positions from Axa IM Prime Impact Master Fund, Sabby Management LLC, and Armistice Capital, alongside early support from the Global Health Investment Fund.